Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-PanTumor03 of trastuzumab deruxtecan in selected HER2-expressing tumors
CTR20233748Phase 2Active
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan in solid neoplasms, sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Objective response rate by independent central review. Started May 2024; status: active.
02
Drugs
trastuzumab deruxtecan
03
Conditions
solid neoplasms
Beyond the preview
Go deeper on CTR20233748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233748.